|

Sipuleucel-T Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: APC 8015, APC-8015, APC8015, APC8015 Vaccine, PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine +3 more

Pipeline

Phase 1: 2Phase 2: 2

Top Sponsors

  • Yale University1
  • University of Oklahoma1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • City of Hope Medical Center1

Indications

  • Cancer4
  • Metastatic Castration-Resistant Prostate Adenocarcinoma1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Metastatic Castration-resistant Prostate Cancer1
  • Stage IVB Prostate Cancer AJCC v81

Duarte, California1 trial

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1

New Haven, Connecticut1 trial

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Yale Cancer Center

Phase 2

Tampa, Florida1 trial

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Moffitt Cancer Center

Phase 2

Oklahoma City, Oklahoma1 trial

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.